GH Research PLC - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
GHRS Nasdaq 2834 www.ghres.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GH Research PLC

Psychedelic: Exclusive talk with biotech company Clearmind Medicine - Mar 22nd, 2025 2:30 pm
Psychedelic: atai Life Sciences, NRx report quarterly results - Mar 21st, 2025 3:50 pm
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - Mar 14th, 2025 3:40 pm
Guggenheim starts GH Research at Buy, sees long-term upside potential - Mar 13th, 2025 9:30 pm
Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 - Mar 3rd, 2025 4:06 pm
GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 - Mar 1st, 2025 4:00 pm
Psychedelic: GH Research, Compass Pathways report earnings results - Feb 28th, 2025 4:30 pm
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates - Feb 27th, 2025 12:00 pm
GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025 - Feb 24th, 2025 6:49 pm
GH Research PLC's (NASDAQ:GHRS) Top Key Executive Florian Schonharting is the most upbeat insider, and their holdings increased by 31% last week - Feb 9th, 2025 2:15 pm
GHRS Stock Rallies 55% in a Week: Here's What You Should Know - Feb 6th, 2025 3:25 pm
GH Research Announces Pricing of $150 Million Public Offering - Feb 5th, 2025 1:52 am
GH Research Announces Proposed Public Offering - Feb 3rd, 2025 9:03 pm
Shares of psychedelics biotech nearly double on depression data - Feb 3rd, 2025 12:07 pm
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction - Feb 3rd, 2025 12:00 pm
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD - Jan 31st, 2025 9:01 pm
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents - Jan 10th, 2025 12:00 pm
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? - Nov 20th, 2024 2:55 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Nov 18th, 2024 12:19 pm
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates - Nov 14th, 2024 12:00 pm